Hamroun S et al for the GR2 Cohort showed that age HR 1.22 and use of NSAIDs HR 3.01 in the pre-conception period was associated with a longer time to conception in women with SpA. Research is needed on continuous NSAID use in the preconception period #EULAR2022 @RheumNow OP0153 https://t.co/hl6jUlK5PN

How many and quickly does nr-AxSpA progress to r-AxSpA? Poddubnyy et al for the PROOF study showed that 16% of nr-AxSpA pts progressed to r-AxSpA within 5 years, mean time to radiographic progression was 2.4 years #EULAR2022 @RheumNow OP0149 https://t.co/KTC8Xkt4ey

Good morning from Copenhagen. Starting the day with looking at imaging in SpA, review of posters, vaccination, lupus nephritis and auto inflammatory disease #EULAR2022 @RheumNow https://t.co/aPEkLjDaK7

ASRI @Gillianfitzger1 @bososhea @Sineadm15 Current smoking is associated with lower risk of uveitis and arthritis in males with axSpA. I wonder why this would be? @RheumNow #EULAR2022 POS1001 https://t.co/3bKmyvI606

Sex differences may affect the response to first line TNFi in AxSpA. Hellamund et al EuroSpA study showed the TNFi 6/12/24 month retention rate was lower in females (58%) compared to males (72%). Females had lower CRP level and higher PROs at baseline #EULAR2022 @RheumNow OP0020 https://t.co/ANgRYMxpat

Upadacitinib shows promising response in the treatment of nr-AxSpA in the SELECT-AXIS 2 study. Deodhar et al showed the ASAS40 response rate for UPA was twice vs placebo (45% vs 23%). 12/14 of the secondary endpoints were also met #EULAR2022 @RheumNow OP0016 https://t.co/dOWVJdLRtG

Updated #EULAR2022 AxSpa Recc: The Algorithm @rheumnow https://t.co/fu46QJ3jmQ

GR2 cohort prospective study of pregnancies in 126 pts w/ SpA over 15 years -Rx exposure 23% steroids, 11% NSAIDS, 55% biologics - 116 live births, 7 miscarriages, 3 stillbirths - 36.5% had unfavorable pregnancy outcomes - 19% SGA - 4.8% preterm birth #EULAR2022 @rheumnow POS1000

SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA as expected: ↘️disease activity ↘️pain and function ↘️QoL at 14 wks no new safety alerts https://t.co/2efpx7Mi6i

AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem to suggest the latest. German GESPIC AxPsA cohort: *More frequently 🚺 *Less frequently B27+ *20% isolated Ax involvement @Rheumnow OP0026 #EULAR2022 https://t.co/FZP9nEyG7J

Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF

• EULAR Abstract Archive

#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria ⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️ ⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️ ⭐️Ankylosis much higher in ♂️ (DOR 40!) @Rheumnow

Hellamand et al. Sex differences in first TNFi response in AxSpA. Treatment efficacy (RR 0.85) and retention (58% vs 72% month 24) rates lower in females. @RheumNow #EULAR2022 OP0020 https://t.co/2IL88K7q40 https://t.co/hSJds5EJFK

• EULAR Abstract Archive